First- and Second-Generation Antipsychotics for Children and Young Adults
Summary of Results: Efficacy of Antipsychotics in Placebo Comparisons (1 of 2)
In the clinical literature about pediatric use of antipsychotics, the review found that second-generation antipsychotics (SGAs) result in greater improvement of disorder-specific symptoms when compared with placebo.
SGAs improve both clinical global impressions (CGIs) and positive and negative symptoms of schizophrenia, an approved indication for their use. The strength of evidence for this conclusion is moderate.
SGAs also improve CGIs and manic but not depressive symptoms of bipolar disorder. The strength of evidence for this conclusion is moderate for CGIs and low for manic and depressive symptoms.
- Seida J, Schouten J, Mousavi S, et al. First- and Second-Generation Antipsychotics for Children and Young Adults. Comparative Effectiveness Review No. 39 (Prepared by the University of Alberta Evidence-based Practice Center under Contract No. 290-2007-10021). Rockville, MD: Agency for Healthcare Research and Quality; February 2012. AHRQ Publication No. 11(12)-EHC077-EF. Available at www.effectivehealthcare.ahrq.gov/pedantipsych.cfm.
Your slide tray is being processed.